Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LIDDS announces today that Markus Thor has been appointed as Head of Business Development and will join the company in March 2019. The employment is a consequence of the enlarged project portfolio...
-
JULI - SEPTEMBER 2018 Nettoomsättningen uppgick till 7,8 (0,2) KSEK Kostnaderna uppgick till 2,5 (1,5) MSEK Resultatet före och efter skatt uppgick till 5,4 (-1,5) MSEK Resultat per aktie uppgick...
-
The National Cancer Institute in Vilnius and the University Clinic of Kaunas are now ready to start inclusion of patients in Part II of the LPC-004 study. Lithuanian authorities have recently...
-
The Life Science Event takes place at Haymarket by Scandic on November 21. CEO Monica Wallter will present the company and update the audience on the latest developments of the NanoZolid technology...
-
The Life Science Event takes place at Haymarket by Scandic on November 21. CEO Monica Wallter will present the company and update the audience on the latest developments of the NanoZolid technology...
-
The Swedish Medical Product Agency has approved a first-in-human study, NZ-DTX-001, in which solid tumors will be treated with NanoZolid combined with docetaxel. This is LIDDS' second clinical...
-
Vid årsstämman i LIDDS AB (publ) den 16 maj 2018 beslutades att en valberedning skall utses och bestå av tre ledamöter, utsedda av de två största aktieägarna per den 30 september 2018, jämte...
-
At BIO-Europe 2018, LIDDS will be meeting potential licensing and collaborative partners, to discuss the recently announced pre-clinical studies with NanoZolid-technology. The STING study is yet...
-
The European Patent Office has approved a novel patent for LIDDS NanoZolid® technology. LIDDS patent protection for the drug delivery technology is now extended for at least another nineteen years. ...
-
ANDRA KVARTALET (APRIL - JUNI 2018) Nettoomsättningen uppgick till 0,0 (0,4) MSEK Kostnaderna uppgick till 2,2 (1,6) MSEK Resultatet före och efter skatt uppgick till -2,2 (-1,2) MSEK ...